Russian Heart Failure Journal 2009year Effectiveness of outpatient switching patients with chronic heart failure from «not recommended» for this disease β-adrenoblockers to nebivolol or bisoprolol

To access this material please log in or register

Register Authorize

Effectiveness of outpatient switching patients with chronic heart failure from «not recommended» for this disease β-adrenoblockers to nebivolol or bisoprolol

Zhubrina E. S., Ovchinnikov A. G., Seredinina E. M., Blankova Z. N., Masenko V. P., Heymets G. I., Ageev F. T.



Urgency. A beneficial effect on the CHF course and prognosis has been demonstrated for only a small number of β-adrenoblockers (BAB). In clinical practive, nevertheless, many patients still stay on BAB with not proven or questionable efficacy in CHF. Aim. Evaluating the effectiveness of switching patients with CHF from the “not recommended” BAB to bisoprolol or nebivolol. Materials and methods. 67 patients with stable II-III FC CHF who had received a standard therapy for CHF including “not recommended” BABs were randomized to bisoprolol (n=35) or nebivolol (n=32) in doses of 1.25 to 10 mg/day (depending on individual tolerance). Clinical status and quality of life (using the Minnesota questionnaire and the visual analogue scale) were assessed in all patients at baseline and after 6 months of therapy. Also a 6-min walking test was performed, echoCG was recorded (to evaluate LV EF), and the serum level of N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured. Results. Switching patients from “not recommended” BAB to bisoprolol and nebivolol was associated with a significant decrease in mean CHF FC; an increase in 6-min walking distance; an improvement in all parameters of quality of life, and an increase in LV EF (for all cases, р<0.01 compared to baseline). Despite that NT-proBNP remained virtually unchanged in all patients, a significant decrease in this parameter (p<0.05) was observed in a subgroup of patients with high baseline NT-proBNP levels (above median). Significant differences in effects on all studied parameters between nebivolol and bisoprolol treatment groups were absent. Therefore switching patients with CHF from “not recommended” BAB to nebivolol or bisoprolol was associated with improvements in their condition, quality of life, LV systolic function, and with reduced levels of NT-proBNP in patients with high levels of this peptide.
  1. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. Эпидемиологические исследования сердечной недостаточности: состояние вопроса. Журнал Сердечная Недостаточность. 2002; 3 (2): 57–58.
  2. American Heart Association. Heart Disease and Stroke Statistics-2004 Update. Dallas, TX: American Heart Association; 2003.
  3. The atlas of heart disease and stroke, Mackay J, Mensah G, editors (World Health Organization, Geneva) 2004. 112 pages.
  4. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29 (19):2388–2442.
  5. ACC / AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112 (12):e154-235.
  6. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная Недостаточность. 2007; 8 (1):4–41.
  7. Flather MD, Shibata MC, Coats AJS, and the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26 (3):215‑225.
  8. Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005; 46 (6):1309–1315.
  9. Беленков Ю. Н., Мареев В. Ю., Скворцов А. А. и др. Клинико-гемодинамические и нейрогуморальные эффекты длительной терапии бета-адреноблокатором бисопрололом больных с тяжелой хронической сердечной недостаточностью. Кардиология. 2003; 43 (10):11–22.
  10. de Groote P, Isnard R, Assyag P et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail. 2007; 9 (12):1205–1211.
  11. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Данелиян М. О. Первые результаты национального эпидемиологического исследования – ЭПидемиологическое Обследование больныХ ХСН в реальной прАктике (по Обращаемости) – ЭПОХА-О-ХСН. Журнал сердечная недостаточность. 2003; 3 (3):116‑120.
  12. Shah SM, Carey IM, DeWilde S et al. Trends and inequities in beta-blocker prescribing for heart failure. Br J Gen Pract. 2008; 58 (557):862‑869.
  13. Guyatt G. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol. 1993; 22 (A):185‑191.
  14. Enright PL, McBurnie MA, Bittner V et al. The 6‑min walk test: a quick measure of functional status in elderly adults. Chest. 2003; 123 (2):387‑398.
  15. Cohn J, Levin T, Olivari M et al. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med. 1984; 311 (13):819‑823.
  16. CIBIS – II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS – II): a randomized trial. Lancet. 1999; 353 (9146):9–13.
  17. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. (COPERNICUS). N Engl J Med. 2001; 344 (22):1651–1658.
  18. Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993; 342 (8885):1441–1446.
  19. The MERIT – HF Study Group. Effects of controlled – release metoprolol on total mortality, hospitalizations, and well – being in patients with heart failure. JAMA. 2000; 283 (10):1295–1302.
  20. Ramahi T, Longo M, Cadariu A et al. Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy. J Am Coll Cardiol. 2001; 37 (3):818‑824.
  21. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Е. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. – М.: «Гэотар-Медиа», 2006. – 432 с.
  22. MERIT-HF study group. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353 (9169):2001–2007.
  23. Packer M, Bristow MR Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334 (21):1349–1355.
  24. Zacà V, Rastogi S, Mishra S et al. Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure. Cardiology. 2009; 112 (4):294‑302.
  25. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail. 2003; 5 (5):621‑627.
  26. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003; 362 (9377):7–13.
  27. Go AS, Yang J, Gurwitz JH et al. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med. 2008; 168 (22):2415–2421.
  28. Kramer JM, Curtis LH, Dupree CS et al. Comparative effectiveness of β-blockers in elderly patients with heart failure. Arch Intern Med. 2008; 168 (22):2422–248.
  29. Diaz A, Bourassa M, Guertin M, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005; 26 (10):967‑974.
  30. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet. 2008; 372 (9641):817‑821.
  31. Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997; 96 (2):509‑516.
  32. Lee SC, Stevens TL, Sandberg SM et al. The potential of brain natriuretic peptide a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail. 2002; 8 (3):149‑154.
  33. Koglin J, Pehlivanli S, Schwaiblmair M et al. Role of brain natriuretic peptide in risk stratification of patient with congestive heart failure. J Am Coll Cardiol. 2001; 38 (7):1934–1941.
  34. Hunt PJ, Richards AM, Nicholls MG et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997; 47 (3):287‑296.
  35. Jourdain P, Funck F, Bellorini M et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail. 2003 Mar; 5 (2):155‑160.
  36. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predict treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001; 37 (2):386‑391.
  37. Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail. 2004; 6 (3):359‑363.
  38. Olsson LG, Swedberg K, Cleland JG et al. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail. 2007; 9 (8):795‑801.
  39. Richards AM, Doughty R, Nicholls MG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001; 37 (7):1781–1787.

To access this material please log in or register

Register Authorize
Ru En